LIVN vs MANE
LivaNova vs Veradermics, Incorporated — AI-powered side-by-side comparison
VS
MANE
Veradermics, Incorporated
71
Buy
| Metric | LIVN | MANE |
|---|
| AI Score |
70
|
71
|
| Price |
$82.25
|
$112.65
|
| P/E Ratio |
23.83×
|
-52.67×
|
| ROE |
-20.2%
|
57.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.2%
|
0.0%
|
| Debt / Equity |
0.27×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
60.6
|
56.7
|
| Beta |
0.872
|
1.3492
|
| Expected Upside |
+0.8%
|
+3.2%
|
AI Committee View
Current Innellis committee reasoning for LIVN versus MANE.
MANE leads by 1 points.
MANE scores 71/100 (Buy) versus LIVN at 70/100 (Buy).
LIVN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- ROE of 15.4% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Risk/reward is unfavorable: 5.6% downside vs 0.8% upside.
MANE Committee View
80% agreement
5 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Risk/reward is unfavorable: 22.3% downside vs 3.2% upside.